Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eltrombopag in Chinese patients with refractory or relapsed severe aplastic anemia
NCT03988608Phase 2Completed
- Sponsor
- Novartis
- Start
- Dec 2019
- Primary completion
- Jul 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of eltrombopag in aplastic anemia, sponsored by Novartis. Primary endpoint: Hematologic Response Rate at 6 Months by Investigator. Started Dec 2019; status: completed.
02
Drugs
eltrombopag
03
Conditions
aplastic anemia
Beyond the preview
Go deeper on NCT03988608.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03988608.